Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifluridine/Tipiracil + Oxaliplatin ± Nivolumab vs FOLFOX ± Nivolumab in Advanced Gastric/Esophageal Cancer
NCT05476796Phase 2Active, not recruiting
- Sponsor
- Unicancer
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Unicancer. Started Jun 2023; status: active, not recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05476796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05476796.